Axsome Therapeutics, Inc.
AXSM
Rank in Stocks
#2367
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Share Price
$157.20
Last synced: 2026-10-21
Market Cap
$8.23B
Change (1 day)
-1.49%
Change (1 year)
21.18%
Country
US
Trade Axsome Therapeutics, Inc. (AXSM)
Category
Healthcare
Stock price history for Axsome Therapeutics, Inc. (AXSM)
Highest end of day price: $166.68 on 2026-10-01
Lowest end of day price: $8.99 on 2015-11-01
Lowest end of day price: $8.99 on 2015-11-01
Stock price history of Axsome Therapeutics, Inc. from 2015 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 25.48% |
| 2025 | 62.10% |
| 2024 | 26.95% |
| 2023 | -4.24% |
| 2022 | 118.74% |
| 2021 | -56.59% |
| 2020 | 11.03% |
| 2019 | 2,538.67% |
| 2018 | -44.64% |
| 2017 | -23.67% |
| 2016 | -25.67% |
| 2015 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
